source
- Analysts Question Biogen's Lupus Drug Litifilimab Ahead of Key Phase 3 ReadoutsAnalysts pressed Biogen CEO Chris Viehbacher during a recent call, focusing on the company's late‑stage pipeline. The discussion centered on litifilimab, Biogen’s experimental lupus therapy, with…
- FDA proposes new rare disease framework to accelerate therapy developmentDuring a public hearing, FDA officials outlined a newly proposed rare disease framework aimed at creating a lasting regulatory scheme. The initiative seeks to speed the development of safe and eff…